RegisterLogin

Nifuratel

CAT: 0804-HY-A0059-01Size: 5 mgDry Ice: NoHazardous: No
CAT#:0804-HY-A0059-01Size:5 mg
Selected
PRICE
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
Nifuratel (NF 113) is an orally active broad-spectrum antibiotic with antiprotozoal, antibacterial, anticancer and anti-inflammatory activities, and has good inhibitory effects on Candida and Trichomonas. Nifuratel is also a STAT3 inhibitor, which significantly inhibits the growth and proliferation of human gastric cancer cells and induces apoptosis. In addition, Nifuratel also inhibits mast cell-mediated antigen hypersensitivity reactions and can be used in the study of IgE-mediated allergic diseases[1][2][3][4][5][6][7][8].
CAS Number
[4936-47-4]
Product Name Alternative
NF 113; SAP 113; Methylmercadone
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Antibiotic; Apoptosis; Bacterial; Fungal; Interleukin Related; Parasite; STAT; TNF Receptor
Type
Reference compound
Related Pathways
Anti-infection; Apoptosis; Immunology/Inflammation; JAK/STAT Signaling; Stem Cell/Wnt
Applications
COVID-19-immunoregulation
Field of Research
Cancer; Infection; Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/nifuratel.html
Purity
99.93
Solubility
DMSO : 50 mg/mL (ultrasonic)
Smiles
O=C1OC(CSC)CN1/N=C/C2=CC=C([N+]([O-])=O)O2
Molecular Formula
C10H11N3O5S
Molecular Weight
285.28
Precautions
H302, H315, H319, H335
References & Citations
[1]Polatti F. Bacterial vaginosis, Atopobium vaginae and nifuratel. Curr Clin Pharmacol. 2012 Feb 1;7 (1) :36-40.|[2]Nijevitch AA, et al. Helicobacter pylori eradication in childhood after failure of initial treatment: advantage of quadruple therapy withnifuratel to furazolidone. Aliment Pharmacol Ther. 2005 Nov 1;22 (9) :881-7.|[3]Nijevitch AA, et al. Nifuratel-containing initial anti-Helicobacter pylori triple therapy in children. Helicobacter. 2007 Apr;12 (2) :132-5.|[4]Xie T, et al. Nifuratel reduces Salmonella survival in macrophages by extracellular and intracellular antibacterial activity[J]. Microbiology Spectrum, 2023, 11 (5) : e05147-22.|[5]Zheng H, et al. Nifuratel, a novel STAT3 inhibitor with potent activity against human gastric cancer cells[J]. Cancer management and research, 2017: 565-572.|[6]Lee J E, et al. Drug repositioning of anti-microbial agent nifuratel to treat mast cell-mediated allergic responses[J]. International Journal of Immunopathology and Pharmacology, 2023, 37: 03946320231202349.|[7]Mendling W, et al. Microbiological and pharmaco-toxicological profile of nifuratel and its favourable risk/benefit ratio for the treatment of vulvo-vaginal infections[J]. Arzneimittelforschung, 2002, 52 (01) : 8-13.|[8]Tynan A P, et al. Nifuratel in urinary infections[J]. British Journal of Urology, 1969, 41 (3) : 271-279.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Launched

Related Products

CatalogName

Alternative Products

CatalogName
RM-N131100-01Nifuratel
RM-N131140-01Nifuratel Impurity 40 ((E) -Nifuratel)
RM-N131113-01Nifuratel Impurity 13 (Homo Nifuratel)
RM-N131123-01(Z) -Nifuratel
TRC-N722345-250MGNifuratel-D5
TRC-N722341-100MGNifuratel-13C2
A13663-100Nifuratel 100mg
TRC-N774560-500MG(R) Nifuratel
TRC-N745330-500MG(S) Nifuratel
A13663-5Nifuratel 5mg

Popular Products